Thrombus News and Research

RSS

A blood clot or thrombus, is the final product of the blood coagulation step in hemostasis. It is achieved via the aggregation of platelets that form a platelet plug, and the activation of the humoral coagulation system (i.e. clotting factors).

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate, received a positive opinion from the European Medicines Agency's medicinal committee today.

16 Apr 2011

Japanese MHLW approves Spectranetics LLD lead locking device

Spectranetics Corporation today announced that the Japanese Ministry of Health, Labor and Welfare granted approval for the LLD lead locking device, which is used for the removal of pacemaker and defibrillator cardiac leads.

6 Apr 2011

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.

28 Mar 2011

FDA grants CSI marketing clearance for Stealth 360° Orbital PAD System

Cardiovascular Systems, Inc. has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), and has begun a limited market release for the Stealth 360°™ Orbital PAD System. The Stealth 360° propels CSI into the forefront of treating peripheral arterial disease (PAD) with a simpler design that gives physicians complete control of device operation.

17 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

BIOTRONIK's new ablation catheter is now available in Europe

BIOTRONIK SE Co. & KG, a leading manufacturer of cardiac devices, has announced that its innovative new ablation catheter, AlCath Flux eXtra Gold, is now available throughout Europe after receiving CE mark and successfully completing the premarket evaluation in Germany, Italy, Switzerland and several other European countries.

9 Mar 2011

New cell therapy can reverse effect of 'bad' LDL cholesterol and reduce atherosclerosis

Researchers at the Swedish medical university Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis.

1 Mar 2011

Hotspur Technologies announces first clinical use of its Keeper Embolectomy Catheter

Hotspur Technologies announced today that Dr. Thomas DiBartholomeo of Fairfield, CT, performed the first clinical use of its Keeper Embolectomy Catheter. The Keeper Catheter enables physicians to clear clot formation within arteries, while also incorporating the capability of injecting physician-specified fluids directly through the balloon catheter.

28 Feb 2011

Spectranetics fourth quarter revenues decrease 1% to $29.3 million

Spectranetics Corporation today reported financial results for the quarter and full year ended December 31, 2010.

17 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

First cases using Concentric Medical's Trevo System for ischemic stroke performed in Canada

Marking a major milestone toward expanding the use of Stentriever™ technology for stroke patients, Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced that the first cases have been performed using its Trevo™ System in Canada.

27 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

FDA approves Spectranetics PMA for manufacturing site change for CVX-300 laser system

Spectranetics Corporation today announced that the Food and Drug Administration (FDA) has approved the Company's premarket approval application (PMA) supplement requesting a manufacturing site change for the CVX-300® laser system.

20 Jan 2011

Kaneka, Atrium Medical introduce FDA-approved Xpress-Way RX Extraction Catheter

Atrium Medical Corporation and Kaneka Corporation are proud to announce the introduction of the Xpress-Way RX Extraction Catheter. Xpress-Way RX has recently received FDA 510K clearance and is indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature.

13 Jan 2011

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Atherosclerosis is the leading cause of death in the developed world. While a number of risk factors for atherosclerosis have been defined, scientists continue to study other possible risk factors for this disease. Recent epidemiological and experimental studies link infectious agents with the development of inflammatory atherosclerosis. A hallmark of chronic infection with the oral pathogen Porphyromonas gingivalis is the induction of a chronic inflammatory response.

5 Jan 2011

Gore releases statement in response to safety of GORE HELEX Septal Occluder for PFO closure in cryptogenic stroke patients

W. L. Gore & Associates (Gore) today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

14 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

MEDRAD to offer RSNA attendees hands-on demonstration on P3T PA software

MEDRAD will offer RSNA attendees hands-on demonstrations of personalized-protocol software that individualizes CT Pulmonary Angiography (CTPA) contrast dosing, and has proven to increase the percentage of diagnostic-quality studies to rule out Pulmonary Embolism (PE) when compared to the institution's standard protocol potentially obviating the need to rescan the patient.

18 Nov 2010

SESAME Stent effective for patients undergoing angioplasty of SVG

A new study revealed that the novel self-expanding super-elastic all-metal endoprosthesis stent (SESAME Stent) used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions has 100% acute success, low 30 day major adverse cardiac events (MACE) rates, and 9-month patency comparable to balloon expandable stents without embolic protection.

17 Nov 2010

InspireMD to launch MGuard Prime MicroNet stent system at TCT Conference

InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010. MGuard Prime presents an advanced Co-Cr Design of 80 micron struts along with InspireMD's unique MicroNet(R) Mesh Technology.

23 Sep 2010